Your browser doesn't support javascript.
loading
Serum thymidine kinase activity in patients with HR-positive/HER2-negative advanced breast cancer treated with ribociclib plus letrozole: Results from the prospective BioItaLEE trial.
Malorni, Luca; Bianchini, Giampaolo; Caputo, Roberta; Zambelli, Alberto; Puglisi, Fabio; Bianchi, Giulia V; Del Mastro, Lucia; Paris, Ida; Montemurro, Filippo; Allegrini, Giacomo; Colleoni, Marco; Tamberi, Stefano; Zamagni, Claudio; Cazzaniga, Marina E; Orditura, Michele; Guarneri, Valentina; Castelletti, Daniela; Benelli, Matteo; Di Marino, Mariacristina; Arpino, Grazia; De Laurentiis, Michelino.
Afiliação
  • Malorni L; Department of Oncology and Translational Research Unit "Sandro Pitigliani", Ospedale di Prato, Azienda USL Toscana Centro, Italy. Electronic address: Luca.malorni@uslcentro.toscana.it.
  • Bianchini G; Department of Oncology, Ospedale San Raffaele, Milano, Italy.
  • Caputo R; Department of Breast and Thoracic Oncology, IRCCS Istituto Nazionale dei Tumori Fondazione G Pascale, Napoli, Italy.
  • Zambelli A; Medical Oncology Unit, IRCCS Humanitas Research Hospital and Department of Biomedical Sciences - Humanitas University, Milano, Italy.
  • Puglisi F; Department of Medical Oncology, IRCCS, Centro di Riferimento Oncologico,Aviano, Italy; Department of Medicine, University of Udine, Italy.
  • Bianchi GV; SC Oncologia Medica 1, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
  • Del Mastro L; U.O.S.D. Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.
  • Paris I; Department of Woman and Child Sciences, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy.
  • Montemurro F; Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Torino, Italy.
  • Allegrini G; U.O.C. Oncologia Medica, Presidio Ospedaliero Livorno, Italy.
  • Colleoni M; Division of Medical Senology, Istituto Europeo di Oncologia (IEO), IRCCS, Milano, Italy.
  • Tamberi S; U.O. Oncologia, P.O. Ospedale degli Infermi - AUSL, Ravenna, Italy.
  • Zamagni C; IRCCS Azienda ospedaliero-universitaria di Bologna, Bologna, Italy.
  • Cazzaniga ME; Phase 1 Research Unit & Oncology Unit, Azienda Socio Sanitaria Territoriale Monza & Milano Bicocca School of Medicine and Surgery, Monza, Italy.
  • Orditura M; U.O.C. Oncologia Medica e Ematologia, A.O.U. Università degli Studi L. Vanvitelli, Napoli, Italy.
  • Guarneri V; Deparment of Surgery, Oncology and Gastroenterology, University of Padova, Italy; Oncologia 2, Istituto Oncologico Veneto (IOV) IRCCS, Padova, Italy.
  • Castelletti D; Oncology, Novartis Farma SpA, Origgio, Italy.
  • Benelli M; Department of Oncology and Bioinformatics Unit, Ospedale di Prato, Azienda USL Toscana Centro, Italy.
  • Di Marino M; Oncology, Novartis Farma SpA, Origgio, Italy.
  • Arpino G; Department of Medical Clinics and Surgery, Università Federico II, Napoli, Italy.
  • De Laurentiis M; Department of Breast and Thoracic Oncology, IRCCS Istituto Nazionale dei Tumori Fondazione G Pascale, Napoli, Italy.
Eur J Cancer ; 186: 1-11, 2023 06.
Article em En | MEDLINE | ID: mdl-37003098
Assuntos
Palavras-chave
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Adicionar na Minha BVS
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Tipo de estudo: Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans Idioma: En Revista: Eur J Cancer Ano de publicação: 2023 Tipo de documento: Article